ARTICLE | Clinical News

Veglin: Phase I data

June 14, 2004 7:00 AM UTC

In a U.S. Phase I trial in 35 patients, Veglin was well tolerated with no dose-limiting toxicities at doses up to 85 µg/m². Veglin lowered blood levels of VEGF-A in 47% of patients and reduced levels ...